Abstract
Introduction: Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life. Discussion: Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 879-889 |
| Number of pages | 11 |
| Journal | Supportive Care in Cancer |
| Volume | 16 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2008 |
All Science Journal Classification (ASJC) codes
- Oncology